OpenLobby.EU
Explore

ResMed

RMD

ResMed (NYSE: RMD, ASX: RMD) manufactures digital health technologies and cloud-connected medical devices transform care for people with sleep apnoea, insomnia, COPD, and other chronic diseases.

Lobbying Activity

Meeting with Fausto Matos (Cabinet of Executive Vice-President Henna Virkkunen)

1 Dec 2025 · Data legislation and Digital Omnibus

Response to EU cardiovascular health plan

16 Sept 2025

Resmed welcomes the European Commission's initiative to develop an EU Cardiovascular Health Plan, aiming to reduce the burden of cardiovascular diseases (CVD) in Europe. As a leading provider of sleep health solutions and as a member of MedTech Europe and DigitalEurope, we at Resmed strongly believe that sleep health must be systematically integrated into CVD prevention, detection and management frameworks. Herewith, we present evidence demonstrating that poor sleep is a significant risk factor for cardiovascular disease and extend our policy recommendations to promote sleep health in the forthcoming EU Cardiovascular Health Plan. Sleep disorders, particularly obstructive sleep apnoea (OSA) and chronic insomnia, directly contribute to the development of hypertension, heart attacks and strokes. The evidence shows that people with untreated OSA are 2-3 times more likely to develop high blood pressure and twice as likely to suffer a heart attack or stroke compared to those without the disorder. Chronic insomnia also increases the risk of high blood pressure and is linked to elevated risks of heart disease and neurological conditions. Sleep disorders rarely exist in isolation and often co-occur with other conditions, such as diabetes, obesity and high cholesterol. This clustering of comorbidities amplifies the overall cardiovascular risk and creates complex patient needs that strain health systems. In fact, the economic and societal burden of untreated sleep disorders is immense. In Europe alone, untreated OSA costs healthcare systems around 34 billion annually, while CVD costs linked to sleep disorders exceed 120 billion per year, accounting for more than 40% of the EUs total CVD expenditure. To strengthen our submission, we attach our position paper providing clinical evidence on the link between sleep and cardiovascular health and underscoring the necessity of addressing both in an integrated manner. The EU has already recognised the role of sleep in major initiatives, including the Council Conclusions on Cardiovascular Health (2024), the European Parliament report on Obesity (2024), and the Healthier Together initiative (2022-2027). Embedding sleep into the EU Cardiovascular Health Plan builds on this momentum and ensures coherence across the EU's broader non-communicable disease (NCD) strategy. To address the critical link between sleep and CVD, we urge the European Commission to recognise sleep health as a vital component of cardiovascular health and address it in the EU Cardiovascular Health Plan. We recommend the inclusion of the following measures: 1. Develop guidelines that promote early diagnosis for sleep disorders in primary and cardiovascular care. 2. All routine cardiovascular risk screening programmes must integrate systematic evaluations for sleep disorders, such as OSA and insomnia, to ensure comprehensive patient care 3. Ensure funding for the treatment and research of sleep disorders to help reduce the economic burden on the EU healthcare system. 4. Enable and embark on public awareness campaigns that highlight the link between sleep and cardiovascular health, noting higher risk of comorbidities. By addressing sleep disorders and promoting sleep health, the EU can reduce the burden of CVD, improve health outcomes and decrease healthcare costs. It is time to prioritise sleep health in policy decisions and make it a core aspect of every citizen's wellbeing.
Read full response

Meeting with Peter Van Kemseke (Cabinet of President Ursula von der Leyen)

10 Oct 2024 · EB Summit

Response to Rationalisation of reporting requirements

28 Nov 2023

ResMed thanks the European Commission for the opportunity to respond to its Call for Evidence on the rationalization of reporting requirements. As a company with a global footprint and with products sold in over 140 countries, we strongly support the commitment to roll back red tape and believe this to be crucial in enhancing EU competitiveness on the world stage. We recognize the significant adjustments made to the European Sustainability Reporting Standards (ESRS) in recent months. The decision to center sustainability reporting around the materiality assessment is a welcome one, as this strikes a balance between significant burden for the reporting entity and preserving access to decision-useful information for stakeholders and investors alike. Performing a materiality assessment rather than just reporting a prescribed set of metrics is key to enable companies to focus their resources on transitioning towards a sustainable business model, rather than on tick-the-box compliance exercises. Converge with international standards The need for continued commitment to international cooperation on the part of EFRAG and the Global Reporting Initiative (GRI) cannot be understated. GRI standards form the basis of the existing reporting system for most international and European companies. It is of utmost important to allow reporting in accordance with both ESRS and GRI standards through one report. Additionally, anything that simplifies the reconciliation of disclosures between the two standards will greatly help companies upgrading their systems. In this context, the announced mapping to be made available by EFRAG is urgently needed. We also encourage intensified cooperation at technical level going forward e.g. on sector-specific standards. Provide implementation guidance for companies In recognition of the challenges preparers will face due to the CSRD requirements, national competent authorities should adopt a supportive approach to enforcement rather than punitive, guiding companies as they implement more robust reporting systems and procedures. We emphasize the importance of consistent implementation guidance and welcome the ongoing work at EFRAG. The guidelines on how to perform a double materiality assessment are a key deliverable, noting that the ESRS delegated act only devotes a few pages to explaining such complex process. Furthermore, we welcome the launch of a formal channel to submit interpretative questions. We also encourage making available to companies key tools like the full list of ESRS data points and the mapping against ISSB standards. The EU should ensure to dedicate appropriate resources for this important work, as part of its administrative simplification efforts. The deployment of smart energy meters would simplify data collection Beyond reporting, we emphasize the importance of standardization and digitalization in other fields to facilitate companies access to structured data for their reports. For instance, smart energy meters enable the automated reporting of emissions pertaining to on-cost/additional facility costs such as heating, electricity, and water. Where smart meters and smart grids have been deployed, this allows for automated data processing and integration into reporting templates, contributing to overall efficiency. More broadly, developing standardised technical specifications and reporting templates in fields like e.g. energy bills, workforce reporting, supply chain due diligence will be of great importance. While we acknowledge this will require time, we believe it will significantly increase efficiency for preparers in the long-term. ResMed would once more like to thank the European Commission for the initiative to reduce the burden on corporates, and looks forward to engaging constructively. Should you have any questions about our submission do not hesitate to reach out to me. Kind regards, Justine Korwek Vandenbosch, Director, Government Affairs EMEA - ResMed
Read full response

Meeting with Maria-Manuel Leitão-Marques (Member of the European Parliament, Rapporteur for opinion)

9 Nov 2022 · Chips Act

Meeting with Petar Vitanov (Member of the European Parliament, Shadow rapporteur)

8 Nov 2022 · EHDS

Meeting with Susana Solís Pérez (Member of the European Parliament, Shadow rapporteur) and BioMarin UK Limited

8 Nov 2022 · EHDS

Meeting with Tomislav Sokol (Member of the European Parliament, Rapporteur)

8 Nov 2022 · European Health Data Space - EHDS

Response to A European Health Data Space

26 Jul 2022

ResMed welcomes the proposal for the European Health Data Space (EHDS) and considers it has great potential to facilitate sharing and using health data, improve primary & secondary care and enhance the secondary use of health data. We would like to point out the following issues that could impact the promise of the EHDS. 1) Risk of fragmentation and hurdles for data access Clear guidance and intent must be developed to inform the significant scope of secondary legislation that is described in the proposal. It is critical that EHDS is integrated with the current EU legislative frameworks (among others the Data Act, MDR and GDPR) and that Member States’ implementation does not lead to fragmentation. Legislators should ensure that secondary legislation does not create a patchy regulatory landscape and that there is a coherent interplay with other applicable legislation. As an example, data access permits from national agencies should be uniform across Member States to reduce duplication and red tape. We note existing good practices in access to data for secondary use. For ResMed, such example is Germany, where data access is granted without untimely delay. However, even there, data is held too short (5 years) to perform certain analyses, e.g. related to mortality. For EHDS implementation, we should avoid creating a system where the process too lengthy or cumbersome (ex. some Member States implementing 2 stage process including data access body & ethics body). Another concern is creation of a possible backlog of request upon EHDS entry into force. 2) Clarity and definitions ResMed considers the current definitions too vague and wide. Examples include Electronic Health Records (EHR), EHR System, data and data holder. Clarification is needed to ensure companies can understand consequences of themselves/their products being classified under those definitions. Key aspects requiring clarity are: payment for data access, mutual recognition of permits across the EU, anonymisation requirements and minimum healthcare data that needs to be included. In addition, it is unclear how the EHDS Regulation will interact with database rights and IP/trade secrets protective legislation. 3) Interoperability to support innovation and avoid harm Protection of intellectual property (IP) is a key issue for innovation and ensuring the EU remains an attractive market for products, research and innovation. Secondary use of data should be inclusive of various uses, including research, to ensure the potential of data is optimized. Providing access to raw data produced by medical devices could cause several issues, both in IP protection and data interpretation. IP-protected data is critical for the commercial operations, ensuring robust R&D capabilities. Sharing raw data could lead to reverse engineering IP-protected solutions. In addition, raw data from ResMed medical devices is not fit to be directly transferred into EHDS as it can be misinterpreted if accessed before being processed by our software. Giving EHDS participants access to raw data could lead to incorrect data interpretations and could have negative impact on patients. At the same time, value of interpretation and analytics should also be protected. This requires setting up minimum standards for data contribution which we believe to be patient health measurements. Companies should be incentivised to volunteer more data, while being able to protect their trade secrets. In addition, devices must not be required to be interoperable with any platform due to increased risk of security that can lead to patient safety risks. Device data must only be made available through cloud-to-cloud APIs thereby allowing the appropriate data insights to be transmitted into EHDS through APIs. ResMed looks forward to engaging on these issues to ensure that the EHDS lives up to its potential and is helpful for all stakeholders in the healthcare sector.
Read full response

Response to Requirements for Artificial Intelligence

30 Jul 2021

Please see ResMed's consultation response for the Artificial Intelligence Act attached below. We thank the Commission for the opportunity to provide feedback on the proposed legislation and welcome further engagement on the regulation of AI in Europe.
Read full response

Meeting with Ursula von der Leyen (President) and

25 Mar 2020 · Videoconference with CEOs on COVID-19